Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan

Advanced Biomed Inc.

Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.
Transaction closed on December 23, 2025; board unanimously approved.
CEO cites evolving China regulatory requirements on clinical trials and data as reason for divestiture.
All clinical trials will now be centralized and conducted through the Taiwan subsidiary.
Buyer Wei Ha Hui is an unrelated third party.

item 1.01item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.